ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,720Medicare Part D Prescriptions Filled, Including Refills

Rank: 120 out of 761

$475K Total Retail Price of All Prescriptions

Rank: 142 out of 761

432 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
29% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 432 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

19% of this provider’s 432 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

2% of this provider’s 8,886 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
LEVOTHYROXINE SODIUM 484 447 1 3
HYDROCODONE-ACETAMINOPHEN 392 329 S3 2 5
LISINOPRIL 352 311 3 1
SIMVASTATIN 330 312 4 2
WARFARIN SODIUM 320 296 5 9
AMLODIPINE BESYLATE 294 267 6 6
FUROSEMIDE 247 239 7 7
METOPROLOL TARTRATE 185 182 8 14
POTASSIUM CHLORIDE 176 166 9 18
OMEPRAZOLE 174 145 10 4
LOVASTATIN 145 120 11 17
METFORMIN HCL 142 128 12 10
ATENOLOL 135 127 13 8
ATORVASTATIN CALCIUM 130 127 14 12
METOPROLOL SUCCINATE 128 123 15 16
ALENDRONATE SODIUM 127 126 16 21
GABAPENTIN 120 117 17 15
PANTOPRAZOLE SODIUM 120 115 17 40
TAMSULOSIN HCL 115 113 19 27
CITALOPRAM HBR 112 108 20 19
LANTUS 108 106 21 41
PREDNISONE 106 94 22 30
LOSARTAN POTASSIUM 104 104 23 13
BENAZEPRIL HCL 86 73 24 112
ZOLPIDEM TARTRATE 82 79 25 22
CIPROFLOXACIN HCL 81 74 26 63
AZITHROMYCIN 79 71 27 70
AGGRENOX 76 76 28 121
KLOR-CON M20 74 72 29 99
GLIPIZIDE 72 62 30 39
HYDROCHLOROTHIAZIDE 71 67 31 11
PAROXETINE HCL 69 69 32 47
GLIMEPIRIDE 68 68 33 48
CARISOPRODOL 67 44 R 34 131
CLOPIDOGREL 64 57 35 66
LEVOFLOXACIN 63 54 36 185
SPIRONOLACTONE 59 59 37 45
OXYCODONE-ACETAMINOPHEN 58 58 S2 38 49
TRAMADOL HCL 56 47 39 34
SYNTHROID 54 51 40 64
CARVEDILOL 53 50 41 26
FENTANYL 52 52 S2 42 57
NABUMETONE 52 47 42 133
LISINOPRIL-HYDROCHLOROTHIAZIDE 52 52 42 35
ACTONEL 52 43 42 171
ETODOLAC 51 50 46 268
TRIAMTERENE-HCTZ 51 39 46 42
DIGOXIN 50 50 48 43
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 25, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.